Read by QxMD icon Read

Journal of Crohn's & Colitis

Cynthia H Seow, Niels Vande Casteele, Remo Panaccione
No abstract text is available yet for this article.
June 14, 2018: Journal of Crohn's & Colitis
Ho-Su Lee, Suk-Kyun Yang, Myunghee Hong, Seulgi Jung, Byoung Mok Kim, Jung Won Moon, Sang Hyoung Park, Byong Duk Ye, Seak Hee Oh, Kyung Mo Kim, Yong Sik Yoon, Chang Sik Yu, Jiwon Baek, Cue Hyunkyu Lee, Buhm Han, Jianjun Liu, Talin Haritunians, Dermot P B McGovern, Kyuyoung Song
Background and Aims: The genetic contribution to the prognosis of ulcerative colitis (UC) is poorly understood, and most currently known susceptibility loci are not associated with prognosis. To identify genetic variants influencing the prognosis of UC, we performed an Immunochip-based study using an extreme phenotype approach. Methods: Based on the finding that the only association Pdiscovery-meta < 1 × 10-4 was located in the human leukocyte antigen (HLA), we focused our analyses on the HLA region...
June 13, 2018: Journal of Crohn's & Colitis
Nazneen R Irani, Lai Mun Wang, Gary S Collins, Satish Keshav, Simon P L Travis
Background and Aims: Endoscopy and histopathology are pivotal for evaluating disease activity in ulcerative colitis (UC); correlation between validated endoscopic and histological indices has not been examined. We aim to correlate the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) with two new validated histological indices in patients with established UC. Methods: A single centre cohort of patients with established UC who underwent flexible sigmoidoscopy or colonoscopy by a single endoscopist...
June 11, 2018: Journal of Crohn's & Colitis
Vildan Binay Safer, Umut Safer
No abstract text is available yet for this article.
June 9, 2018: Journal of Crohn's & Colitis
Luisa Guidi, Daniela Pugliese, Tommaso Panici Tonucci, Alexandra Berrino, Barbara Tolusso, Michele Basile, Laura Cantoro, Paola Balestrieri, Fortunata Civitelli, Lorenzo Bertani, Manuela Marzo, Carla Felice, Elisa Gremese, Francesco Costa, Franca Viola, Michele Cicala, Anna Kohn, Antonio Gasbarrini, Gian Lodovico Rapaccini, Matteo Ruggeri, Alessandro Armuzzi
Background: Empirical dose intensification and therapeutic drug monitoring (TDM) of infliximab (IFX) trough levels (ITL) and antibody (ATI) assays are recognised approaches for managing the loss of response (LoR) in inflammatory bowel disease (IBD) patients. Aim: To compare these two interventions in a clinical setting, in terms of effectiveness and cost savings. Methods: Consecutive IBD patients, experiencing LoR, were clinically managed according to a TDM algorithm...
May 31, 2018: Journal of Crohn's & Colitis
Stephane Paul, Nicolas Williet, Thomas Di Bernado, Anne-Emmanuelle Berger, Gilles Boschetti, Jerome Filippi, Emilie Del Tedesco, Stephane Nancey, Bernard Flourie, Xavier Roblin
Background: Vedolizumab (VDZ), a humanized monoclonal antibody targeting α4β7 integrin, is effective in induction and maintenance therapy in patients with inflammatory bowel disease (IBD) who have not adequately responded to standard therapies, and high levels of vedolizumab trough levels (VTL) have been associated with clinical remission. The α4β7 integrin binds to endothelial MAdCAM-1 and is up-regulated by retinoic acid (RA). Aim: To determine the relations between soluble MAdCAM-1 (sMAdCAM-1) and RA concentrations with clinical remission during VDZ maintenance therapy...
May 31, 2018: Journal of Crohn's & Colitis
Felicia M Bloemendaal, Pim J Koelink, Karin A van Schie, Theo Rispens, Charlotte P Peters, Christianne J Buskens, Jarmila D van der Bilt, Willem A Bemelman, Hannelie Korf, João G Sabino, Cyriel Y Ponsioen, Anje A Te Velde, Geert R A M D'Haens, Gijs R van den Brink, Manon E Wildenberg
Background and Aims: We have recently shown that the mode of action of IgG1 anti-TNF antibodies in inflammatory bowel disease (IBD) requires Fcγ-receptor (FcR) engagement on macrophages. Here we examine the effect of Fcγ-receptor signaling by anti-TNF on macrophage IL-12/IL-23 secretion. Methods: Cytokine production by human inflammatory macrophages was assessed at the level of RNA and or protein. TNF-anti-TNF immune complex formation was determined by size-exclusion chromatography and signaling visualized by immunofluorescence...
May 30, 2018: Journal of Crohn's & Colitis
Stefan Schreiber, Corey A Siegel, Keith A Friedenberg, Ziad H Younes, Ursula Seidler, Bal R Bhandari, Ke Wang, Emily Wendt, Matt McKevitt, Sally Zhao, John S Sundy, Scott D Lee, Edward V Loftus
Background and Aims: Matrix metalloproteinase-9 (MMP9) is implicated in the pathogenesis of Crohn's disease and may serve as a potential biomarker. A phase 2 trial was conducted to examine the efficacy and safety of the anti-MMP9 antibody, andecaliximab (GS-5745), in patients with moderately to severely active Crohn's disease. Methods: Patients were randomized 1:2:2:2 to receive subcutaneous injections of placebo weekly (QW), andecaliximab 150 mg every 2 weeks (Q2W), andecaliximab 150 mg QW, or andecaliximab 300 mg QW...
May 29, 2018: Journal of Crohn's & Colitis
Maisa Abdalla, Hans Herfarth
No abstract text is available yet for this article.
May 26, 2018: Journal of Crohn's & Colitis
Oren Ledder, Peter Church, Ruth Cytter-Kuint, Maria Martínez-León, Malgorzata Sladek, Eva Coppenrath, Batia Weiss, Baruch Yerushalmi, Javier Martin de Carpi, Larisa Duchano, Alexander Towbin, Amit Assa, Ron Shaoul, M L Mearin, George Alex, Anne Griffiths, Dan Turner
Objective: There is no standardized endoscopic description of upper gastrointestinal (UGI) disease in Crohn's disease (CD). We prospectively applied the Simple Endoscopic Score for CD (SES-CD) to the UGI tract as a planned sub-study of the multicenter prospective ImageKids study. We aimed to assess the utility of the UGI-SES-CD and its clinical significance in pediatric CD. Design: Patients underwent an esophagogastroduodenoscopy (EGD), ileocolonoscopy and magnetic resonance enterography (MRE) with explicit clinical data recorded...
May 25, 2018: Journal of Crohn's & Colitis
Samuel O Adegbola, Kapil Sahnan, Philip J Tozer, Raimund Strouhal, Ailsa L Hart, Phillip Fc Lung, Robin Ks Phillips, Omar Faiz, Janindra Warusavitarne
Methods: Consecutive patients with complex Crohn's fistula undergoing a VAAFT for symptomatic Crohn's anal fistula were included. They were identified from a prospectively maintained database, which was interrogated from June 2015-November 2017. Patients underwent diagnostic fistuloscopy and fulguration of tracts/secondary extensions. Setons were sited/replaced after the procedure to maintain postoperative drainage. Primary endpoint was completion of the "Measure your medical outcome profile" (MYMOP2) quality of life (QoL) questionnaire at 6 weeks postoperatively...
May 25, 2018: Journal of Crohn's & Colitis
M Belvis Jiménez, B Maldonado Pérez, F Argüelles-Arias
No abstract text is available yet for this article.
May 19, 2018: Journal of Crohn's & Colitis
Fabienne Charbit-Henrion, Marianna Parlato, Sylvain Hanein, Rémi Duclaux-Loras, Jan Nowak, Bernadette Begue, Sabine Rakotobe, Julie Bruneau, Cécile Fourrage, Olivier Alibeu, Frédéric Rieux-Laucat, Eva Lévy, Marie-Claude Stolzenberg, Fabienne Mazerolles, Sylvain Latour, Christelle Lenoir, Alain Fischer, Capucine Picard, Marina Aloi, Jorge Amil Dias, Mongi Ben Hariz, Anne Bourrier, Christian Breuer, Anne Breton, Jiri Bronski, Stephan Buderus, Mara Cananzi, Stéphanie Coopman, Clara Crémilleux, Alain Dabadie, Clémentine Dumant-Forest, Odul Egritas Gurkan, Alexandre Fabre, Aude Fischer, Marta German Diaz, Yago Gonzalez-Lama, Olivier Goulet, Graziella Guariso, Neslihan Gurcan, Matjaz Homan, Jean-Pierre Hugot, Eric Jeziorski, Evi Karanika, Alain Lachaux, Peter Lewindon, Rosa Lima, Fernando Magro, Janos Major, Georgia Malamut, Emmanuel Mas, Istvan Mattyus, Luisa M Mearin, Jan Melek, Victor Manuel Navas-Lopez, Anders Paerregaard, Cecile Pelatan, Bénédicte Pigneur, Isabel Pinto Pais, Julie Rebeuh, Claudio Romano, Nadia Siala, Caterina Strisciuglio, Michela Tempia-Caliera, Patrick Tounian, Dan Turner, Vaidotas Urbonas, Stéphanie Willot, Frank M Ruemmele, Nadine Cerf-Bensussan
Background and Aims: An expanding number of monogenic defects have been identified as causative of severe forms of very early-onset inflammatory bowel diseases (VEO-IBD). The present study aimed at defining how next-generation sequencing (NGS) methods can be used to improve identification of known molecular diagnosis and adapt treatment. Methods: 207 children were recruited in 45 Paediatric centres through an international collaborative network (ESPGHAN GENIUS working group) with a clinical presentation of severe VEO-IBD (n=185) or an anamnesis suggestive of a monogenic disorder (n=22)...
May 18, 2018: Journal of Crohn's & Colitis
Charlotte K Brierley, Cristina Castilla-Llorente, Myriam Labopin, Manuela Badoglio, Montserrat Rovira, Elena Ricart, Daan Dierickx, Severine Vermeire, Peter Hasselblatt, Juergen Finke, Francesco Onida, Andrea Cassinotti, Jack Satsangi, Majid Kazmi, Antonio López-Sanromán, Carsten Schmidt, Dominique Farge, Simon P L Travis, Chris J Hawkey, John A Snowden
Background/Aims: Autologous haematopoietic stem cell transplantation (AHSCT) is a therapeutic option for patients with severe, treatment-refractory Crohn's disease (CD). The evidence base for AHSCT for CD is limited, with one randomised trial (ASTIC) suggesting benefit. The aim of this study was to evaluate safety and efficacy for patients undergoing AHSCT for CD in Europe outside the ASTIC trial. Methods: We identified 99 patients in the European Society for Blood and Marrow Transplantation (EBMT) registry who were eligible for inclusion...
May 18, 2018: Journal of Crohn's & Colitis
Brian G Feagan, Fatima Bhayat, Mona Khalid, Aimee Blake, Simon P L Travis
Background and Aims: Vedolizumab, a humanised monoclonal antibody for the treatment of inflammatory bowel disease, selectively blocks gut lymphocyte trafficking. This may reduce the risk of respiratory tract infections [RTIs] compared with systemic immunosuppressive therapies. To assess this possibility, we evaluated the rates of RTIs in clinical trials of vedolizumab. Methods: Patient-level data from Phase 3 randomised controlled trials [RCTs] of vedolizumab in ulcerative colitis [UC; GEMINI 1] and Crohn's disease [CD; GEMINI 2], and a long-term safety study [UC and CD] were pooled...
May 17, 2018: Journal of Crohn's & Colitis
Shannon L Kanis, Alison de Lima, Cokkie van der Ent, Dimitris Rizopoulos, C Janneke van der Woude
Background and Aims: Pregnancy guidelines for women with Inflammatory Bowel Disease (IBD) provide recommendations regarding anti-TNF cessation during pregnancy, in order to limit fetal exposure. Although infliximab (IFX) leads to higher anti-TNF concentrations in cord blood than adalimumab (ADA), recommendations are similar. We aimed to demonstrate the effect of anti-TNF cessation during pregnancy on fetal exposure, for IFX and ADA separately. Methods: We conducted a prospective single center cohort study...
May 15, 2018: Journal of Crohn's & Colitis
Christopher A Lamb, Sharon O'Byrne, Mary E Keir, Eugene C Butcher
Integrins are cell surface receptors with bi-directional signaling capabilities that can bind to adhesion molecules in order to mediate homing of leukocytes to peripheral tissues. Gut-selective leukocyte homing is facilitated by interactions between α4β7 and its ligand MAdCAM-1, while retention of lymphocytes in mucosal tissues is mediated by αEβ7 binding to its ligand E-cadherin. Therapies targeting gut-selective trafficking have shown efficacy in inflammatory bowel disease (IBD), confirming the importance of leukocyte trafficking in disease pathobiology...
May 15, 2018: Journal of Crohn's & Colitis
William J Sandborn, Bal R Bhandari, Charles Randall, Ziad H Younes, Tomasz Romanczyk, Yan Xin, Emily Wendt, Hao Chai, Matt McKevitt, Sally Zhao, John S Sundy, Satish Keshav, Silvio Danese
Background and Aims: Matrix metalloproteinase-9 [MMP9] is implicated in the pathogenesis of ulcerative colitis [UC] via disruption of intestinal barrier integrity and function. A phase 2/3 combined trial was designed to examine the efficacy, safety, and pharmacokinetics of the anti-MMP9 antibody, andecaliximab [formerly GS-5745], in patients with moderately to severely active UC. Methods: Patients were randomised [1:1:1] to receive placebo, 150 mg andecaliximab every 2 weeks [Q2W], or 150 mg andecaliximab weekly [QW], via subcutaneous administration...
May 14, 2018: Journal of Crohn's & Colitis
Kelly C Cushing, Hamed Kordbacheh, Michael S Gee, Avinash Kambadakone, Ashwin N Ananthakrishnan
Background: Acute severe ulcerative colitis (ASUC) affects one in four patients with UC. Clinical parameters perform modestly in predicting need for rescue therapy. Sarcopenia and visceral adiposity predict natural history in Crohn's disease, but the role of such metabolic factors on ASUC outcomes is unknown. Aim: To define the effect of sarcopenia and visceral adiposity on outcomes in ASUC. Methods: We studied patients hospitalized for ASUC who underwent an abdominal CT scan during the hospitalization...
May 12, 2018: Journal of Crohn's & Colitis
Chen Yang, Junlin Huang, Xiaowen Huang, Shaozhuo Huang, Jiaxin Cheng, Weixin Liao, Xuewen Chen, Xueyi Wang, Shixue Dai
Background and Aims: The association between anti-tumor necrosis factor alpha agents and the risk of lymphoma in patients with inflammatory bowel disease has already been sufficiently reported. However, the results of these studies are inconsistent. Hence, this analysis was conducted to investigate whether anti-tumor necrosis factor alpha agents can increase the risk of lymphoma in inflammatory bowel disease patients. Methods: MEDLINE, EMBASE and the Cochrane Library were searched to identify relevant studies which evaluated the risk of lymphoma in inflammatory bowel disease patients treated with anti-tumor necrosis factor alpha agents...
May 12, 2018: Journal of Crohn's & Colitis
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"